Date:3/15/2010

ions to provide users with the ability to view identical marks across all sources searched;

A summary pharmaceutical information box, showing safety information about a mark;

Name safety, providing detail from Prescription Drug User Fee Act 4 sources, including: Orange Book, Drugs@FDA, AERS, VAERS, USAN Names and Stems and Pharma In-Use; and

The industry's first full integration of the FDA's POCA across sources and including POCA rankings.

"The pharmaceutical search adds a wealth of information that flags where there are real potential issues," said Susan Upton Douglass a partner at Fross, Zelnick, Lehrman & Zissu. "It was amazing to see all of these resources brought together in such an organized and useful way. This enhanced search report is really cutting edge, making the other products now obsolete."

About CT Corsearch

CT Corsearch provides high-quality, intuitive tools and expertise that trademark professionals need to effectively manage the trademark screening, search review and watching processes.  Its highly trained researchers and customer-designed tools enable the company to offer the premier solutions in the industry.  For more information, please visit

SOURCE CT Corsearch Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study